Literature DB >> 7310126

Hepatitis in dialysis units in the United Kingdom: a Public Health Laboratory Service Survey.

S Polakoff.   

Abstract

A prospective study of hepatitis that began in 1968 and continues to include more than half the dialysis units in the United Kingdom shows that type B infection has been completely controlled in such units since the last outbreak ended in 1973. Though occasionally a single patient has developed hepatitis B surface antigenaemia in the course of dialysis or after transplantation, the infection has not spread to other patients or staff in the survey units. A detailed analysis of the results in 1974-75 shows clustering of patients with raised aminotransferase levels in about one-fifth of the units but, unlike past outbreaks of hepatitis B, these clusters are not accompanied by clinical hepatitis among staff. The possibility that some of the clusters are caused by hepatitis viruses other than type A or B is discussed. It is concluded that, when reliable tests for type non-A non-B infections become available, the continued existence of the survey will allow prompt assessment of any viral hepatitis problems that may still exist in UK units.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7310126      PMCID: PMC2134117          DOI: 10.1017/s0022172400069692

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  10 in total

1.  [Non-A, non-B hepatitis in hemodialysis patients: medicamentous etiology].

Authors:  P Simon; A Meyrier; M Menault; D Bombail
Journal:  Nouv Presse Med       Date:  1979-03-24

2.  Hepatitis in a maintenance hemodialysis unit.

Authors:  J B Eastwood; J R Curtis; A J Wing; H E de Wardener
Journal:  Ann Intern Med       Date:  1968-07       Impact factor: 25.391

3.  Plasticizers in P.V.C. and the occurrence of hepatitis in a haemodialysis unit. A preliminary communication.

Authors:  J Neergaard; B Nielsen; V Faurby; D H Christensen; O F Nielsen
Journal:  Scand J Urol Nephrol       Date:  1971

4.  Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients.

Authors:  J Crosnier; P Jungers; A M Couroucé; A Laplanche; E Benhamou; F Degos; B Lacour; P Prunet; Y Cerisier; P Guesry
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

5.  Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff.

Authors:  J Crosnier; P Jungers; A M Couroucé; A Laplanche; E Benhamou; F Degos; B Lacour; P Prunet; Y Cerisier; P Guesry
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

6.  Chronic liver disease developing after outbreak of HBsAG-negative hepatitis in haemodialysis unit.

Authors:  R M Galbraith; A L Eddleston; B Portmann; R Williams; P E Gower
Journal:  Lancet       Date:  1975-11-08       Impact factor: 79.321

7.  Hepatitis in dialysis units in the United Kingdom.

Authors:  S Polakoff; Y E Cossart; H E Tillett
Journal:  Br Med J       Date:  1972-07-08

8.  Reactivation of hepatitis b after transplantation operations.

Authors:  J Nagington
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

9.  Hepatitis B vaccine: immune responses in haemodialysis patients.

Authors:  C E Stevens; W Szmuness; A I Goodman; S A Weseley; M Fotino
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321

10.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

  10 in total
  2 in total

1.  Negative selection of patients for dialysis and transplantation in the United Kingdom.

Authors:  V Parsons; M Bewick; S A Snowden; A Eddleston; P M Lock; A H Uttley
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-02

2.  Detection of antibodies to hepatitis C virus in dialysis patients.

Authors:  D Rivanera; D Lilli; G Lorino; V Pirozzi; V Cannulla; G Dicuonzo; C Mancini
Journal:  Eur J Epidemiol       Date:  1993-01       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.